High–Throughput Microarray Technologies: From Genomics to Clinics

Background: Despite continuous research efforts in the past decades, there are still cancers where no effective treatment is available, such as advanced kidney cancer or hormone–refractory prostate cancer. A better understanding of the molecular mechanisms of cancer development and progression is the basis for the development of new diagnostic and therapeutic strategies. Current developments in genomics have a dramatic impact on the whole field of research. The sequence of the entire human genome will soon be fully sequenced and provide the ‘book of life’ as a basis for the understanding of human disease. Methods and Results: New technologies have emerged to translate the human genome sequence into gene function and improved diagnostics or treatment modalities. New technologies such as microarrays are not only important for fundamental research, but will also be useful for diagnostic, prognostic or therapeutic purposes in individual patients. DNA microarrays make it possible to analyze the mRNA expression of thousands of genes simultaneously. The resulting comprehensive gene expression surveys lead to the identification of new genes and pathways with importance in cancer development and progression, or as targets for new therapies. The validation and prioritization of genes emerging from genome screening analyses in large series of clinical tumors has become a new bottleneck in research. Therefore, we have recently developed the tissue microarray (TMA) technology to efficiently test the clinical relevance of candidate genes. TMAs are microscope slides containing samples from hundreds of individual tumor specimens. They can be used for large–scale, massively parallel in situ analysis of genetic alterations on a DNA, RNA and protein level using in situ hybridization or immunohistochemistry on hundreds of tumor specimens at a time. Microarray technologies are already increasingly being used in urologic research, and will also have a strong impact on clinical urology. Conclusions: DNA microarrays and TMAs provide a powerful approach to identify large numbers of new candidate genes, and rapidly validate their clinical impact in large series of human tumors. These technologies will soon lead to a better molecular understanding of urologic tumors, and accelerate the identification of new prognostic markers or therapeutic targets.

[1]  L. Penland,et al.  Use of a cDNA microarray to analyse gene expression patterns in human cancer , 1996, Nature Genetics.

[2]  M. Bittner,et al.  Expression profiling using cDNA microarrays , 1999, Nature Genetics.

[3]  D. Bentley The Human Genome Project--an overview. , 2000, Medicinal research reviews.

[4]  R. Narayanan,et al.  Microarray-based expression profiling in prostate tumors. , 2000, In vivo.

[5]  M. Rubin,et al.  Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. , 2000, Human pathology.

[6]  D. Clemmons Role of insulin-like growth factor binding proteins in controlling IGF actions , 1998, Molecular and Cellular Endocrinology.

[7]  D. Bowtell,et al.  Options available—from start to finish—for obtaining expression data by microarray , 1999, Nature Genetics.

[8]  T C Gasser,et al.  Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. , 1999, Cancer research.

[9]  D. Peehl,et al.  Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. , 1991, The Journal of clinical endocrinology and metabolism.

[10]  M. Rubin,et al.  Tissue microarray assessment of prostate cancer tumor proliferation in African- American and white men. , 2000, Journal of the National Cancer Institute.

[11]  Howell DNA Microarrays for Analysis of Gene Expression. , 1999, Molecular urology.

[12]  Y. Chen,et al.  Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. , 2000, Journal of the National Cancer Institute.

[13]  Ji Huang,et al.  [Serial analysis of gene expression]. , 2002, Yi chuan = Hereditas.

[14]  D. Botstein,et al.  Exploring the new world of the genome with DNA microarrays , 1999, Nature Genetics.

[15]  L. Cardon,et al.  Waiting for the working draft from the human genome project , 2000, BMJ : British Medical Journal.

[16]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[17]  H. Moch,et al.  High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. , 1999, The American journal of pathology.

[18]  P. Smaglik Genome leaders told to keep their eyes on the main prize , 2000, Nature.

[19]  O. Kallioniemi,et al.  Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. , 2000, Cancer research.

[20]  S. P. Fodor,et al.  High density synthetic oligonucleotide arrays , 1999, Nature Genetics.

[21]  E Mahlamäki,et al.  Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. , 1999, Journal of the National Cancer Institute.

[22]  F. Collins,et al.  Shattuck lecture--medical and societal consequences of the Human Genome Project. , 1999, The New England journal of medicine.

[23]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[24]  H. Moch,et al.  Tissue microarrays for gene amplification surveys in many different tumor types. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  L. Sapinoso,et al.  Functional dissection of transcriptional profiles in androgen-dependent and -independent prostate cancer , 2001, Nature Genetics.

[26]  E. Lander Array of hope , 1999, Nature Genetics.

[27]  J. Hudson,et al.  Development of a prostate cDNA microarray and statistical gene expression analysis package , 2000, Molecular carcinogenesis.

[28]  T Hardmeier,et al.  High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. , 2000, The American journal of pathology.

[29]  Howell Sb DNA Microarrays for Analysis of Gene Expression. , 1999 .